Compare Adaptive Biotechnologies Corp (ADPT) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bank of New York Mellon Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Bank of New York Mellon Corp trades at $160.21 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 26.9× Adaptive Biotechnologies Corp's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BNY | |
|---|---|---|
Market Cap | $4.04B | $108.78B |
Sector | Health | Financials |
52-Week High | $25.45 | $162.35 |
52-Week Low | $12.30 | $101.00 |
Enterprise Value | $4.10B | — |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.
The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
